HAVN Life Announces a 30:1 Consolidation of its Common Shares
July 29, 2022 16:30 ET
|
HAVN Life Sciences Inc.
VANCOUVER, British Columbia, July 29, 2022 (GLOBE NEWSWIRE) -- HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company” or "HAVN Life") a biotechnology company pursuing...
HAVN Life Launches the Brain Evolve Series
April 13, 2022 07:00 ET
|
HAVN LIFE SCIENCES INC.
VANCOUVER, British Columbia, April 13, 2022 (GLOBE NEWSWIRE) -- HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company developing natural...
HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research
February 24, 2022 08:00 ET
|
HAVN Life Sciences Inc.; Revive Therapeutics Ltd.
VANCOUVER, British Columbia, Feb. 24, 2022 (GLOBE NEWSWIRE) -- HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing...
Havn Life Sciences announces increase in Bought Deal Financing to $10 Million
December 15, 2020 10:01 ET
|
Havn Life Sciences Inc.
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Havn Life Sciences Inc. (CSE : HAVN) (FSE :...
Havn Life Sciences announces $5 million Bought Deal Financing
December 15, 2020 07:30 ET
|
Havn Life Sciences Inc.
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP)...